Guggenheim initiated coverage on Precision BioSciences with a new price target
$DTIL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Guggenheim initiated coverage of Precision BioSciences with a rating of Buy and set a new price target of $19.00